Results 101 to 110 of about 358,966 (235)
Interval Timing Is Altered in Male Nrxn1+/− Mice: A Model of Autism Spectrum Disorder
Autism Research, EarlyView.ABSTRACT Autism spectrum disorder (ASD) is characterized by impaired social interactions and communication, and increased repetitive and stereotypical behavior. Neuroimaging shows functional abnormalities in brain areas involved in temporal processing in autistic individuals, and they also show deficits in interval timing.
Kyle M. Roddick +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Neuropsychiatry of Parkinson's Disease
Parkinson's Disease, 2012 Antonio L. Teixeira +3 more
doaj +1 more source
Clinical pharmacology consultations and their implementation in clinical decision making
British Journal of Clinical Pharmacology, EarlyView.Aims One of the key roles of clinical pharmacologists is to work as consultants for other medical specialties. We wanted to investigate the characteristics of clinical pharmacology consultations, compare the types of consultations from different specialties, and evaluate how well the recommendations given were followed.
Mirjam Kauppila +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto +5 more
wiley +1 more source
Brain Health, EarlyView.ABSTRACT The World Health Organization (WHO) defines brain health as the maintenance of optimal brain integrity, good mental state, and cognitive function without significant neuropsychiatric disease. Early childhood is a critical period for brain development, which were influenced by early experiences, nutrition, and environmental factors. Disruptions
Yu Ma +5 more
wiley +1 more source